Business description: Scholar Rock Holding Corporation

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

Number of employees: 289

Sales by Activity: Scholar Rock Holding Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Pharmaceuticals

18.82M 33.19M - - -

Geographical breakdown of sales: Scholar Rock Holding Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

18.82M 33.19M - - -

Executive Committee: Scholar Rock Holding Corporation

Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Tech/Sci/R&D Officer 51 2022-08-31
Chief Tech/Sci/R&D Officer 48 2025-01-28
Chief Operating Officer 58 2025-04-26

Composition of the Board of Directors: Scholar Rock Holding Corporation

Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Director/Board Member 70 2013-10-31
Director/Board Member 63 2019-05-20
Director/Board Member 53 2021-03-17
Director/Board Member 58 2022-07-25
Director/Board Member 68 2023-04-05
Director/Board Member 55 2024-02-14

Shareholders: Scholar Rock Holding Corporation

NameStocks%Valuation
Fidelity Management & Research Co. LLC
15.01 %
17,243,152 15.01 % 948 M $
The Invus Group LLC
9.423 %
10,825,013 9.423 % 595 M $
The Invus Group LLC
9.423 %
10,825,013 9.423 % 595 M $
Redmile Group LLC
7.892 %
9,066,621 7.892 % 499 M $
BlackRock Advisors LLC
6.084 %
6,989,380 6.084 % 384 M $

Company details: Scholar Rock Holding Corporation

Scholar Rock Holding Corp.

301 Binney Street

02142, Cambridge

+857 259 3860

http://www.scholarrock.com
address Scholar Rock Holding Corporation(SRRK)

Bio Therapeutic Drugs

Change 5-day change 1-year change 3-year change Capi.($)
+2.18%-6.79%+23.33%+631.12% 6.33B
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.28%-3.04%+39.03%+228.53% 23.99B
Weighted average by Cap. -2.67%-2.47%+39.68%+156.96%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
52.86USD
Average target price
59.31USD
Spread / Average Target
+12.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock
  4. Company Scholar Rock Holding Corporation